Research Blog

COVID-19: Blood Biomarkers - Neutrophils

Neutrophils are not neutral in COVID-19

Dicken Weatherby, N.D. and Beth Ellen DiLuglio, MS, RDN, LDN

Neutrophils are the first white blood cell responders during an infection. Lymphocytes are the white blood cells that become B cells or T cells. Calculating the ratio between them provides important clues to inflammatory state and prognosis in COVID-19.

The ODX COVID-19 Series

  1. COVID-19: The pandemic that has become endemic
  2. COVID-19: Overlapping risk factors and chronic disease
  3. Nutritional status COVID-19: A covert factor in disease susceptibility
  4. COVID-19: Blood chemistry biomarker patterns - Clues and patterns lurking just under the surface
  5. COVID-19: Blood chemistry biomarker patterns - Down the research rabbit hole
  6. COVID-19: Blood Biomarkers - Neutrophils
  7. COVID-19: Blood Biomarkers - Albumin
  8. COVID-19: BloodBiomarkers - Cytokines
  9. COVID-19: Blood Biomarkers - Interleukin-6
  10. COVID-19: Blood Biomarkers - Interleukin-10
  11. COVID-19: Blood Biomarkers - Vitamin C
  12. COVID-19: Blood Biomarkers - Vitamin D
  13. COVID-19: Blood Biomarkers - Zinc
  14. Biomarker characteristics and blood type - help sharpen the COVID-19 clinical picture
  15. COVID-19: Initial indications and conventional interventions
  16. COVID-19: Long-term risk reduction - Naturopathic, functional medicine, and nutrition-based approaches to prevention
  17. A healthy diet is primary prevention for COVID-19
  18. You should have a gut feeling about COVID-19
  19. Beyond dietary food patterns…plant-based compounds may mitigate COVID-19 risk
  20. Targeted nutrition support in the battle against COVID-19
  21. Targeted nutrition support in COVID-19: Armed with vitamin C
  22. Targeted nutrition support in COVID-19: In sync with zinc
  23. Targeted nutrition support in COVID-19: Micronutrients and phytonutrients are important players
  24. Optimal Takeaways for improving immunity and reducing susceptibility to COVID-19
  25. Optimal - The Podcast: Episode 8 -Blood Biomarkers and Risk Factors for COVID-19 and its Comorbidities

Neutrophil:Lymphocyte Ratio (NLR)

The neutrophil-lymphocyte ratio serves as a biomarker of inflammation.

When comparing severe to non-severe COVID-19 cases, a meta-analysis of 15 studies revealed that individuals with severe COVID-19 presented with higher neutrophils and neutrophil:lymphocyte ratios, and lower lymphocyte counts.[i]

Meta-analysis of 13 studies comprising 1579 patients found that NLR provided good predictive value for assessing disease severity and mortality in COVID-19. For disease severity, the positive likelihood ratio was 3.6 (negative likelihood at NLR 0.2) and for mortality, the positive likelihood ratio was 4.8, though some studies established a “high cutoff value” of 6.5 or greater.[ii]

In an Italian cohort of 74 hospitalized COVID-19 patients, a median NLR of 5.6 was associated with severe disease, and an NLR greater than 4 was associated with transfer to the ICU. An NLR below 3 was associated with clinical improvement.[iii]

One study of 81 COVID-19 patients found that an NLR of greater than 9.8 was associated with significantly higher rates of acute respiratory distress syndrome and mechanical ventilation.[iv]

A retrospective study of 139 hospitalized COVID-19 patients considered NLR values to be independent predictors of disease severity and mortality with optimal thresholds of 3.27 and 5.72, respectively. The study also found BUN/Creatinine ratios independently predicted severe disease and mortality with optimal thresholds of 33.5 and 51.7, respectively. A number of lab parameters differed significantly between severe and non-severe disease: [v]

Biomarker Severe Non-severe
BUN 46 23.8 mg/dl
BUN:Creatinine ratio 50.3 24.2
CRP 53.6 14.2 mg/dl
Lymphocyte count 1.16 1.48 10^9/L
Monocyte:Lymphocyte ratio 0.4 0.27
Neutrophil count 6.33 3.99 10^9/L
Neutrophil:Lymphocyte ratio  6.1 2.46
WBC - Total 8.1 6.1 10^9/L

Optimal Takeaway

Assessing and monitoring the neutrophil:lymphocyte ratio is an invaluable tool for gauging severity and potential improvement in COVID-19.

Next Up - COVID-19: Blood Biomarkers - Albumin

Research

[i] Zeng, Furong et al. “Can we predict the severity of coronavirus disease 2019 with a routine blood test?.” Polish archives of internal medicine vol. 130,5 (2020): 400-406. doi:10.20452/pamw.15331

[ii] Li, Xiaoming et al. “Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis.” Critical care (London, England) vol. 24,1 647. 16 Nov. 2020, doi:10.1186/s13054-020-03374-8

[iii] Ciccullo, Arturo et al. “Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line.” International journal of antimicrobial agents vol. 56,2 (2020): 106017. doi:10.1016/j.ijantimicag.2020.106017

[iv] Gallo Marin, Benjamin et al. “Predictors of COVID-19 severity: A literature review.” Reviews in medical virology, e2146. 30 Jul. 2020, doi:10.1002/rmv.2146

[v] Ok, Fesih et al. “Predictive values of blood urea nitrogen/creatinine ratio and other routine blood parameters on disease severity and survival of COVID-19 patients.” Journal of medical virology, 10.1002/jmv.26300. 14 Jul. 2020, doi:10.1002/jmv.26300

Want to Keep Reading?

This article is free to read with an Optimal DX account. Create your free account now for full access, no card required. Already have an account? Log in.

Tag(s): Biomarkers

Other posts you might be interested in